A Novel Non-Opioid Multimodal Analgesic from Xgene Pharmaceutical Reduces Pain and a Need for Opioid Consumption in a Post-Surgical Pain Trial

After-hours movers: HPE, lululemon, Ulta Beauty, Docusign and more

SHANGHAI--(BUSINESS WIRE)-- Xgene Pharmaceutical announced additional insights into the positive results of a multiple-center, placebo-controlled, dose-ranging Phase 2b study (registration number: NCT06017999) in patients undergoing bunionectomy, evaluating the safety and efficacy of the XG005 oral tablet on acute pain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241231349875/en/

XG005 is a non-opioid, new chemical entity with dual mode of action in targeting both nociceptive and neuropathic pain signals. The placebo, 750 mg or 1250 mg of XG005, was administered orally twice a day (bid) for 72 hours to patients undergoing bunionectomy. The study was collaborated with Evolution Research Group and Lotus Clinical Research at multiple sites in the USA. A total of 450 subjects were enrolled into the trial with 1:1:1 randomization ratio. The drug was well tolerated with an acceptable safety profile. There were no drug-related serious adverse events.

The primary and the key secondary efficacy endpoints of SPI over 48 hours for the 1250 mg and 750 mg dose group versus placebo achieved statistically significant difference, respectively with 1250 mg dose providing significantly more analgesia than 750 mg.

Other efficacy endpoints are briefly listed below:

"I have not seen any analgesics showing such great efficacy in well-controlled multiple center trials. Mean pain severity was mild at the most in high dose group versus severe in placebo group. The amount of rescue medication used, including opioids, was less than 1/3 in the high dose arm compared with placebo. The standard effect sizes for the primary (high dose) and the key secondary (low dose) efficacy endpoints are 1.55 and 1.28, respectively. This compelling efficacy of XG005 overwhelmingly distinguishes it from other analgesics and we are extremely encouraged to expedite the development for early delivery to patients." said Leon Jiang, Chief Medical Officer at Xgene Pharmaceutical.

"There is a substantial need for more efficacious, safer, non-opioid treatment for acute pain, as many patients are unable to get sufficient relief with currently available medicines due to intolerable side effects. We are pleased that the results from this trial showed the excellent therapeutic effect of XG005, with the potential to be a better treatment option compared to current therapies," said Gene Hsu, CEO of Xgene. "Xgene is proud to continue its efforts on this unique product, moving forward with great confidence."

About Acute Pain

Acute pain is defined as pain lasting less than 3 months. In 2023, the acute pain market was valued at approximately USD 50.03 billion and project to reach around USD 78.36 billion by 2032. Due to limited non-opioid treatment options, there is an unmet need in acute pain management to improve the patient experience and reduce the economic and societal burden. (Acute Pain Market Size, Share, Trends & Report | 2032)

About XG005

XG005 is a novel molecule targeting two distinct pain pathways: an anti-nociceptive and an anti-neuropathic. It is potentially first-in-class oral treatment that is in parallel development for treatment of acute and chronic pain conditions. Due to its dual mechanism of action, XG005 is potentially able to provide greater inhibition of the pain signal transmission achieving better analgesic outcomes while providing good safety profile.

A positive phase 2b trial results of XG005 treatment in chronic osteoarthritis pain was recently reported, and a Phase 2 trial of XG005 in cancer-induced bone pain is currently ongoing in Taiwan and Mainland of China.

About Xgene Pharmaceutical: Transforming Medicine for Better Lives

At Xgene, we apply new clinical findings, science, and innovative technology to bring therapies to patients to extend and significantly improve their lives. We strive for quality, safety and value in our new products. Our goal is to deliver the world's best medicine to patients worldwide. Xgene's drug discovery areas include pain and CNS conditions focusing research on finding treatments and cures for unmet medical needs. We collaborate with health care providers, governments, and local communities to identify patient needs and deliver reliable, affordable medicines around the world. Visit our website at www.xgenepharm.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241231349875/en/

Direct further inquiries to Dr. Iwona Beczkowska [email protected]